Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia

Harmony Estelle Black, BSc, Satpal Jhujh, Grant S Stewart, BSc, PhD, Kienan I Savage, PhD, Ken I Mills, PhD FRCPath, BSc

Blood (2019) 134 (Supplement_1): 1255.

https://doi.org/10.1182/blood-2019-129828

Published: 2019

Journal Articles

Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study)

Katrina Lappin, PhD BSc, Kyle B Matchett, PhD, Jaine Blayney, PhD, Ken I Mills, PhD FRCPath, BSc

Blood (2018) 132 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2018-99-111234

Published: 2018

Journal Articles

Relationship between HUWE1 Mutation and Functionality in Multiple Myeloma

Lisa J Crawford, BSc, PhD, David Campbell, BSc, PhD, Ken I Mills, PhD FRCPath, BSc, Alexandra E Irvine, PhD FRCPath

Blood (2018) 132 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2018-99-118294

Published: 2018

Journal Articles

The Potential of Using DNA Damage Repair Deficiency As a Biomarker for Cytarabine Response in AML Patients

Clare Crean, BA, MSc, Kienan I Savage, PhD, Ken I Mills, PhD FRCPath, BSc

Blood (2018) 132 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2018-99-115854

Published: 2018

Journal Articles

Loss of Function Cohesin Complex Gene Mutations Create Neomorphic Cell States Advantageous to Oncogenesis

James S Smith, BSc (Hons), Kienan I Savage, PhD, Alexander Thompson, PhD, Ken I Mills, PhD, FRCPath

Blood (2016) 128 (22): 1564.

https://doi.org/10.1182/blood.V128.22.1564.1564

Published: 2016

Journal Articles

Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance

Laura M Kettyle, BSc, Ivan Grishagin, PhD, Glenda J Dickson, PhD, Charles-Etienne Lebert-Ghali, PhD, Janetta Jacoba Bijl, PhD, Mary Frances McMullin, MD FRCPath, FRCP, Terence R.J. Lappin, PhD FRCPath, Ken I Mills, PhD, FRCPath, Alexander Thompson, PhD

Blood (2015) 126 (23): 3630.

https://doi.org/10.1182/blood.V126.23.3630.3630

Published: 2015

Journal Articles

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

Blood (2013) 122 (21): 743.

https://doi.org/10.1182/blood.V122.21.743.743

Published: 2013

Journal Articles

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Blood (2013) 122 (21): 52.

https://doi.org/10.1182/blood.V122.21.52.52

Published: 2013

Journal Articles

Identifying an Acetylation Signature Following Vorinostat Treatment in AML

Jodie F Hay, Fabio G Liberante, Clare McCourt, PhD, Kathleen A O'Hagan, PhD, Ken I Mills, PhD

Blood (2012) 120 (21): 1291.

https://doi.org/10.1182/blood.V120.21.1291.1291

Published: 2012

Journal Articles

Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients

Jaspal S Kaeda, PhD, Christian Oberender, Daniel Neuman, Theo Kim, MD, Ken I Mills, PhD, Anna Serra, PhD, Philipp Hemmati, MD, Regina Schleede, Tim Overkamp, Frauke Ringel, PhD, Thomas Pretzsch, Seval Turkmen, MD, Michaela Schwarz, MD, Renate Arnold, MD, Bernd Dörken, MD, Philipp le Coutre, MD

Blood (2012) 120 (21): 1449.

https://doi.org/10.1182/blood.V120.21.1449.1449

Published: 2012

Journal Articles

Epigenetic Silencing of BCL2 , ETS1 , IL27RA and DICER1 in Low-Risk MDS Patients

Mónica del Rey, Kathleen O'Hagan, Margaret Dellett, Sara Aibar, Hilary A. A. Colyer, María Eugenia Alonso, María Diez-Campelo, Richard N. Armstrong, Daniel J. Sharpe, Norma C. Gutiérrez, Juan Luis García, Javier de las Rivas, Ken I Mills, PhD, Jesús M. Hernández-Rivas

Blood (2012) 120 (21): 1704.

https://doi.org/10.1182/blood.V120.21.1704.1704

Published: 2012

Journal Articles

Arrested Differentiation in Acute Myeloid Leukemia (AML) with Silenced Ankyrin Repeat and SOCS Box Protein 3 (ASB3) Expression

Gemma Logan, Nicolas Rapin, Bo T. Porse, PhD, Melanie J Percy, PhD, FRCPath, Ken I Mills, PhD

Blood (2012) 120 (21): 1232.

https://doi.org/10.1182/blood.V120.21.1232.1232

Published: 2012

Journal Articles

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Blood (2012) 120 (21): 1399.

https://doi.org/10.1182/blood.V120.21.1399.1399

Published: 2012

Journal Articles

Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes

Andrea Pellagatti, Axel Benner, Dipl.Stat., Ken I Mills, PhD, Mario Cazzola, Aristoteles Giagounidis, MD, Janet Perry, Luca Malcovati, Matteo G Della Porta, Martin Jadersten, Amit Verma, Emma-Jane McDonald, Sally Killick, Eva Hellstrom-Lindberg, Lars Bullinger, MD, PhD, James S Wainscoat, Jacqueline Boultwood, MD

Blood (2012) 120 (21): 3857.

https://doi.org/10.1182/blood.V120.21.3857.3857

Published: 2012

Journal Articles

Increased MSI2 expression Is Associated with Aggressive CML and AML

Blood (2011) 118 (21): 2516.

https://doi.org/10.1182/blood.V118.21.2516.2516

Published: 2011

Journal Articles

Therapeutic Potential of Targeted HOXA-TALE Knockdown in AML,

Glenda Joanne Dickson, PhD, Kathleen A O'Hagan, PhD, Damian PJ Finnegan, MRCP, FRCPath, PhD, Mary Frances McMullin, MD, Ken I. Mills, PhD, FRCPath, Terence R.J. Lappin, PhD, FRCPath, Alexander Thompson, BSc, MSc, PhD

Blood (2011) 118 (21): 3460.

https://doi.org/10.1182/blood.V118.21.3460.3460

Published: 2011

Journal Articles

Histone H3 Methylation Mediates All- Trans -Retinoic Acid Responsiveness in Acute Myeloid Leukemia

Tino Schenk, PhD, Stefanie Göllner, PhD, Weihsu Claire Chen, PhD, Louise Howell, BSc, Liqing Jin, MD, Katja Hebestreit, Hans-Ulrich Klein, PhD, Alan K Burnett, MD, Ken I. Mills, PhD, FRCPath, Laurence Marton, MD, Robert Casero, Jr., PhD, Patrick Woster, PhD, Martin Dugas, MD, Jean C.Y. Wang, MD, PhD, John E. Dick, PhD, Carsten Müller-Tidow, MD, Kevin Petrie, PhD, Arthur Zelent, PhD

Blood (2011) 118 (21): 224.

https://doi.org/10.1182/blood.V118.21.224.224

Published: 2011

Journal Articles

Differential Gene and MicroRNA Expression In a HOXA9-MEIS1 Model of Leukemia

Joanne Margaret Ramsey, BSc, Glenda Joanne Dickson, PhD, Janetta Jacoba Bijl, PhD, Ken I. Mills, PhD, FRCPath, Terence R.J. Lappin, PhD, FRCPath, Guy Sauvageau, MD, PhD, FRCPC, Alexander Thompson, PhD

Blood (2010) 116 (21): 64.

https://doi.org/10.1182/blood.V116.21.64.64

Published: 2010

Journal Articles

Epor Over-Expression In TEL-AML1 Positive ALL: Critical Roles for DNA Methylation, GATA-2 or MicroRNAs?

Marie Breen, Vivien Hodges, Bsc, PhD, Marketa Zaliova, MD, Jan Trka, MD, PhD, Terence R.J. Lappin, PhD, FRCPath, Ken I. Mills, PhD, FRCPath

Blood (2010) 116 (21): 3619.

https://doi.org/10.1182/blood.V116.21.3619.3619

Published: 2010

Journal Articles

The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group

Blood (2008) 112 (11): 753.

https://doi.org/10.1182/blood.V112.11.753.753

Published: 2008

NARROW

STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia

Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study)

Relationship between HUWE1 Mutation and Functionality in Multiple Myeloma

The Potential of Using DNA Damage Repair Deficiency As a Biomarker for Cytarabine Response in AML Patients

Loss of Function Cohesin Complex Gene Mutations Create Neomorphic Cell States Advantageous to Oncogenesis

Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Identifying an Acetylation Signature Following Vorinostat Treatment in AML

Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients

Epigenetic Silencing of BCL2 , ETS1 , IL27RA and DICER1 in Low-Risk MDS Patients

Arrested Differentiation in Acute Myeloid Leukemia (AML) with Silenced Ankyrin Repeat and SOCS Box Protein 3 (ASB3) Expression

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes

Increased MSI2 expression Is Associated with Aggressive CML and AML

Therapeutic Potential of Targeted HOXA-TALE Knockdown in AML,

Histone H3 Methylation Mediates All- Trans -Retinoic Acid Responsiveness in Acute Myeloid Leukemia

Differential Gene and MicroRNA Expression In a HOXA9-MEIS1 Model of Leukemia

Epor Over-Expression In TEL-AML1 Positive ALL: Critical Roles for DNA Methylation, GATA-2 or MicroRNAs?

The Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Sub-Classification of Leukemia: Final Report on 3252 Cases from the International MILE Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only